Catálogo de publicaciones - revistas
Nature
Resumen/Descripción – provisto por la editorial en inglés
Nature is a weekly international journal publishing the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde jul. 2012 / hasta dic. 2023 | Nature.com | ||
| No detectada | desde jul. 2006 / hasta ago. 2012 | Ovid |
Información
Tipo de recurso:
revistas
ISSN impreso
0028-0836
ISSN electrónico
1476-4687
Editor responsable
Springer Nature
País de edición
Reino Unido
Fecha de publicación
1869-
Tabla de contenidos
Centimetre-scale perovskite solar cells with fill factors of more than 86 per cent
Jun Peng
; Felipe Kremer; Daniel Walter; Yiliang Wu; Yi Ji; Jin Xiang; Wenzhu Liu; The Duong; Heping Shen; Teng Lu; Frank Brink; Dingyong Zhong; Li Li; Olivier Lee Cheong Lem; Yun Liu; Klaus J. Weber; Thomas P. White; Kylie R. Catchpole
Palabras clave: Multidisciplinary.
Pp. 573-578
Age of the oldest known Homo sapiens from eastern Africa
Céline M. Vidal; Christine S. Lane; Asfawossen Asrat; Dan N. Barfod; Darren F. Mark; Emma L. Tomlinson; Amdemichael Zafu Tadesse; Gezahegn Yirgu; Alan Deino; William Hutchison; Aurélien Mounier; Clive Oppenheimer
<jats:title>Abstract</jats:title><jats:p>Efforts to date the oldest modern human fossils in eastern Africa, from Omo-Kibish<jats:sup>1–3</jats:sup> and Herto<jats:sup>4,5</jats:sup> in Ethiopia, have drawn on a variety of chronometric evidence, including <jats:sup>40</jats:sup>Ar/<jats:sup>39</jats:sup>Ar ages of stratigraphically associated tuffs. The ages that are generally reported for these fossils are around 197 thousand years (kyr) for the Kibish Omo I<jats:sup>3,6,7</jats:sup>, and around 160–155 kyr for the Herto hominins<jats:sup>5,8</jats:sup>. However, the stratigraphic relationships and tephra correlations that underpin these estimates have been challenged<jats:sup>6,8</jats:sup>. Here we report geochemical analyses that link the Kamoya’s Hominid Site (KHS) Tuff<jats:sup>9</jats:sup>, which conclusively overlies the member of the Omo-Kibish Formation that contains Omo I, with a major explosive eruption of Shala volcano in the Main Ethiopian Rift. By dating the proximal deposits of this eruption, we obtain a new minimum age for the Omo fossils of 233 ± 22 kyr. Contrary to previous arguments<jats:sup>6,8</jats:sup>, we also show that the KHS Tuff does not correlate with another widespread tephra layer, the Waidedo Vitric Tuff, and therefore cannot anchor a minimum age for the Herto fossils. Shifting the age of the oldest known <jats:italic>Homo sapiens</jats:italic> fossils in eastern Africa to before around 200 thousand years ago is consistent with independent evidence for greater antiquity of the modern human lineage<jats:sup>10</jats:sup>.</jats:p>
Palabras clave: Multidisciplinary.
Pp. 579-583
A high-resolution picture of kinship practices in an Early Neolithic tomb
Chris Fowler; Iñigo Olalde; Vicki Cummings; Ian Armit; Lindsey Büster; Sarah Cuthbert; Nadin Rohland; Olivia Cheronet; Ron Pinhasi; David Reich
Palabras clave: Multidisciplinary.
Pp. 584-587
Large-scale migration into Britain during the Middle to Late Bronze Age
Nick Patterson; Michael Isakov; Thomas Booth; Lindsey Büster; Claire-Elise Fischer; Iñigo Olalde; Harald Ringbauer; Ali Akbari; Olivia Cheronet; Madeleine Bleasdale; Nicole Adamski; Eveline Altena; Rebecca Bernardos; Selina Brace; Nasreen Broomandkhoshbacht; Kimberly Callan; Francesca Candilio; Brendan Culleton; Elizabeth Curtis; Lea Demetz; Kellie Sara Duffett Carlson; Ceiridwen J. Edwards; Daniel M. Fernandes; M. George B. Foody; Suzanne Freilich; Helen Goodchild; Aisling Kearns; Ann Marie Lawson; Iosif Lazaridis; Matthew Mah; Swapan Mallick; Kirsten Mandl; Adam Micco; Megan Michel; Guillermo Bravo Morante; Jonas Oppenheimer; Kadir Toykan Özdoğan; Lijun Qiu; Constanze Schattke; Kristin Stewardson; J. Noah Workman; Fatma Zalzala; Zhao Zhang; Bibiana Agustí; Tim Allen; Katalin Almássy; Luc Amkreutz; Abigail Ash; Christèle Baillif-Ducros; Alistair Barclay; László Bartosiewicz; Katherine Baxter; Zsolt Bernert; Jan Blažek; Mario Bodružić; Philippe Boissinot; Clive Bonsall; Pippa Bradley; Marcus Brittain; Alison Brookes; Fraser Brown; Lisa Brown; Richard Brunning; Chelsea Budd; Josip Burmaz; Sylvain Canet; Silvia Carnicero-Cáceres; Morana Čaušević-Bully; Andrew Chamberlain; Sébastien Chauvin; Sharon Clough; Natalija Čondić; Alfredo Coppa; Oliver Craig; Matija Črešnar; Vicki Cummings; Szabolcs Czifra; Alžběta Danielisová; Robin Daniels; Alex Davies; Philip de Jersey; Jody Deacon; Csilla Deminger; Peter W. Ditchfield; Marko Dizdar; Miroslav Dobeš; Miluše Dobisíková; László Domboróczki; Gail Drinkall; Ana Đukić; Michal Ernée; Christopher Evans; Jane Evans; Manuel Fernández-Götz; Slavica Filipović; Andrew Fitzpatrick; Harry Fokkens; Chris Fowler; Allison Fox; Zsolt Gallina; Michelle Gamble; Manuel R. González Morales; Borja González-Rabanal; Adrian Green; Katalin Gyenesei; Diederick Habermehl; Tamás Hajdu; Derek Hamilton; James Harris; Chris Hayden; Joep Hendriks; Bénédicte Hernu; Gill Hey; Milan Horňák; Gábor Ilon; Eszter Istvánovits; Andy M. Jones; Martina Blečić Kavur; Kevin Kazek; Robert A. Kenyon; Amal Khreisheh; Viktória Kiss; Jos Kleijne; Mark Knight; Lisette M. Kootker; Péter F. Kovács; Anita Kozubová; Gabriella Kulcsár; Valéria Kulcsár; Christophe Le Pennec; Michael Legge; Matt Leivers; Louise Loe; Olalla López-Costas; Tom Lord; Dženi Los; James Lyall; Ana B. Marín-Arroyo; Philip Mason; Damir Matošević; Andy Maxted; Lauren McIntyre; Jacqueline McKinley; Kathleen McSweeney; Bernard Meijlink; Balázs G. Mende; Marko Menđušić; Milan Metlička; Sophie Meyer; Kristina Mihovilić; Lidija Milasinovic; Steve Minnitt; Joanna Moore; Geoff Morley; Graham Mullan; Margaréta Musilová; Benjamin Neil; Rebecca Nicholls; Mario Novak; Maria Pala; Martin Papworth; Cécile Paresys; Ricky Patten; Domagoj Perkić; Krisztina Pesti; Alba Petit; Katarína Petriščáková; Coline Pichon; Catriona Pickard; Zoltán Pilling; T. Douglas Price; Siniša Radović; Rebecca Redfern; Branislav Resutík; Daniel T. Rhodes; Martin B. Richards; Amy Roberts; Jean Roefstra; Pavel Sankot; Alena Šefčáková; Alison Sheridan; Sabine Skae; Miroslava Šmolíková; Krisztina Somogyi; Ágnes Somogyvári; Mark Stephens; Géza Szabó; Anna Szécsényi-Nagy; Tamás Szeniczey; Jonathan Tabor; Károly Tankó; Clenis Tavarez Maria; Rachel Terry; Biba Teržan; Maria Teschler-Nicola; Jesús F. Torres-Martínez; Julien Trapp; Ross Turle; Ferenc Ujvári; Menno van der Heiden; Petr Veleminsky; Barbara Veselka; Zdeněk Vytlačil; Clive Waddington; Paula Ware; Paul Wilkinson; Linda Wilson; Rob Wiseman; Eilidh Young; Joško Zaninović; Andrej Žitňan; Carles Lalueza-Fox; Peter de Knijff; Ian Barnes; Peter Halkon; Mark G. Thomas; Douglas J. Kennett; Barry Cunliffe; Malcolm Lillie; Nadin Rohland; Ron Pinhasi; Ian Armit; David Reich
Palabras clave: Multidisciplinary.
Pp. 588-594
Spatial maps in piriform cortex during olfactory navigation
Cindy Poo; Gautam Agarwal; Niccolò Bonacchi; Zachary F. Mainen
Palabras clave: Multidisciplinary.
Pp. 595-599
Human blastoids model blastocyst development and implantation
Harunobu Kagawa; Alok Javali; Heidar Heidari Khoei; Theresa Maria Sommer; Giovanni Sestini; Maria Novatchkova; Yvonne Scholte op Reimer; Gaël Castel; Alexandre Bruneau; Nina Maenhoudt; Jenna Lammers; Sophie Loubersac; Thomas Freour; Hugo Vankelecom; Laurent David; Nicolas Rivron
<jats:title>Abstract</jats:title><jats:p>One week after fertilization, human embryos implant into the uterus. This event requires the embryo to form a blastocyst consisting of a sphere encircling a cavity lodging the embryo proper. Stem cells can form a blastocyst model that we called a blastoid<jats:sup>1</jats:sup>. Here we show that naive human pluripotent stem cells cultured in PXGL medium<jats:sup>2</jats:sup> and triply inhibited for the Hippo, TGF-β and ERK pathways efficiently (with more than 70% efficiency) form blastoids generating blastocyst-stage analogues of the three founding lineages (more than 97% trophectoderm, epiblast and primitive endoderm) according to the sequence and timing of blastocyst development. Blastoids spontaneously form the first axis, and we observe that the epiblast induces the local maturation of the polar trophectoderm, thereby endowing blastoids with the capacity to directionally attach to hormonally stimulated endometrial cells, as during implantation. Thus, we propose that such a human blastoid is a faithful, scalable and ethical model for investigating human implantation and development<jats:sup>3,4</jats:sup>.</jats:p>
Palabras clave: Multidisciplinary.
Pp. 600-605
A naturally inspired antibiotic to target multidrug-resistant pathogens
Zongqiang Wang; Bimal Koirala; Yozen Hernandez; Matthew Zimmerman; Steven Park; David S. Perlin; Sean F. Brady
Palabras clave: Multidisciplinary.
Pp. 606-611
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
Samuel J. Vidal; Elena Bekerman; Derek Hansen; Bing Lu; Kelly Wang; Judy Mwangi; William Rowe; Federico Campigotto; Jim Zheng; Darryl Kato; Abishek Chandrashekar; Julia Barrett; Shivani Patel; Huahua Wan; Tochi Anioke; Noe B. Mercado; Joseph P. Nkolola; Melissa J. Ferguson; William J. Rinaldi; Christian Callebaut; Wade Blair; Tomas Cihlar; Romas Geleziunas; Stephen R. Yant; Dan H. Barouch
<jats:title>Abstract</jats:title><jats:p>Because no currently available vaccine can prevent HIV infection, pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) is an important tool for combating the HIV pandemic<jats:sup>1,2</jats:sup>. Long-acting ARVs promise to build on the success of current PrEP strategies, which must be taken daily, by reducing the frequency of administration<jats:sup>3</jats:sup>. GS-CA1 is a small-molecule HIV capsid inhibitor with picomolar antiviral potency against a broad array of HIV strains, including variants resistant to existing ARVs, and has shown long-acting therapeutic potential in a mouse model of HIV infection<jats:sup>4</jats:sup>. Here we show that a single subcutaneous administration of GS-CA1 provides long-term protection against repeated rectal simian–human immunodeficiency virus (SHIV) challenges in rhesus macaques. Whereas all control animals became infected after 15 weekly challenges, a single 300 mg kg<jats:sup>−</jats:sup><jats:sup>1</jats:sup> dose of GS-CA1 provided per-exposure infection risk reduction of 97% for 24 weeks. Pharmacokinetic analysis showed a correlation between GS-CA1 plasma concentration and protection from SHIV challenges. GS-CA1 levels greater than twice the rhesus plasma protein-adjusted 95% effective concentration conferred 100% protection in this model. These proof-of-concept data support the development of capsid inhibitors as a novel long-acting PrEP strategy in humans.</jats:p>
Palabras clave: Multidisciplinary.
Pp. 612-616
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
Jonas S. Heitmann; Tatjana Bilich; Claudia Tandler; Annika Nelde; Yacine Maringer; Maddalena Marconato; Julia Reusch; Simon Jäger; Monika Denk; Marion Richter; Leonard Anton; Lisa Marie Weber; Malte Roerden; Jens Bauer; Jonas Rieth; Marcel Wacker; Sebastian Hörber; Andreas Peter; Christoph Meisner; Imma Fischer; Markus W. Löffler; Julia Karbach; Elke Jäger; Reinhild Klein; Hans-Georg Rammensee; Helmut R. Salih; Juliane S. Walz
<jats:title>Abstract</jats:title><jats:p>T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins<jats:sup>1,2</jats:sup>, combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, aiming to induce profound SARS-CoV-2 T cell immunity to combat COVID-19. Here we conducted a phase I open-label trial, recruiting 36 participants aged 18–80 years, who received a single subcutaneous CoVac-1 vaccination. The primary end point was safety analysed until day 56. Immunogenicity in terms of CoVac-1-induced T cell response was analysed as the main secondary end point until day 28 and in the follow-up until month 3. No serious adverse events and no grade 4 adverse events were observed. Expected local granuloma formation was observed in all study participants, whereas systemic reactogenicity was absent or mild. SARS-CoV-2-specific T cell responses targeting multiple vaccine peptides were induced in all study participants, mediated by multifunctional T helper 1 CD4<jats:sup>+</jats:sup> and CD8<jats:sup>+</jats:sup> T cells. CoVac-1-induced IFNγ T cell responses persisted in the follow-up analyses and surpassed those detected after SARS-CoV-2 infection as well as after vaccination with approved vaccines. Furthermore, vaccine-induced T cell responses were unaffected by current SARS-CoV-2 variants of concern. Together, CoVac-1 showed a favourable safety profile and induced broad, potent and variant of concern-independent T cell responses, supporting the presently ongoing evaluation in a phase II trial for patients with B cell or antibody deficiency.</jats:p>
Palabras clave: Multidisciplinary.
Pp. 617-622
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut; Mireia Crispin-Ortuzar; Suet-Feung Chin; Elena Provenzano; Helen A. Bardwell; Wenxin Ma; Wei Cope; Ali Dariush; Sarah-Jane Dawson; Jean E. Abraham; Janet Dunn; Louise Hiller; Jeremy Thomas; David A. Cameron; John M. S. Bartlett; Larry Hayward; Paul D. Pharoah; Florian Markowetz; Oscar M. Rueda; Helena M. Earl; Carlos Caldas
<jats:title>Abstract</jats:title><jats:p>Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment<jats:sup>1</jats:sup>. The composition of these tumour ecosystems and interactions within them contribute to responses to cytotoxic therapy<jats:sup>2</jats:sup>. Efforts to build response predictors have not incorporated this knowledge. We collected clinical, digital pathology, genomic and transcriptomic profiles of pre-treatment biopsies of breast tumours from 168 patients treated with chemotherapy with or without HER2 (encoded by <jats:italic>ERBB2</jats:italic>)-targeted therapy before surgery. Pathology end points (complete response or residual disease) at surgery<jats:sup>3</jats:sup> were then correlated with multi-omic features in these diagnostic biopsies. Here we show that response to treatment is modulated by the pre-treated tumour ecosystem, and its multi-omics landscape can be integrated in predictive models using machine learning. The degree of residual disease following therapy is monotonically associated with pre-therapy features, including tumour mutational and copy number landscapes, tumour proliferation, immune infiltration and T cell dysfunction and exclusion. Combining these features into a multi-omic machine learning model predicted a pathological complete response in an external validation cohort (75 patients) with an area under the curve of 0.87. In conclusion, response to therapy is determined by the baseline characteristics of the totality of the tumour ecosystem captured through data integration and machine learning. This approach could be used to develop predictors for other cancers.</jats:p>
Palabras clave: Multidisciplinary.
Pp. 623-629